More receptor activation in the stomach and intestines means slower stomach emptying, which is already the primary mechanism of action
When claims are drawn from these sources, they are attributed to "Omzo's published materials" or "per Omzo's Terms." FDA.gov primary sources: The FDA's public page on unapproved GLP-1 drugs, the April 30, 2026 FDA press release on the 503B Bulks List proposal, and the Federal Register notice 91 Fed
HealthCare.gov
Durability and Sustained Weight Loss Clinical trials show that weight loss from GLP-1 receptor agonists is sustained over time, particularly when combined with lifestyle changes
This publication does not independently substantiate, verify, or endorse those promotional phrases as performance guarantees
The evidence base for the ingredients used in GLP-1 support is built almost entirely on oral delivery